NCT06390826 2026-03-17
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT02068586 2026-03-16
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Thomas Jefferson University
Phase 2 Active not recruiting
NCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03091192 2026-01-23
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT03541902 2026-01-09
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00329043 2025-12-26
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00715442 2025-12-23
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05734105 2025-12-17
INSIGHT
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT06208748 2025-10-31
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Sarcoma Alliance for Research through Collaboration
Phase 2 Active not recruiting
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05043090 2025-05-08
SAMETA
AstraZeneca
Phase 3 Active not recruiting